{
    "clinical_study": {
        "@rank": "104224", 
        "arm_group": [
            {
                "arm_group_label": "TPX-100 Cohort 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee"
            }
        ], 
        "brief_summary": {
            "textblock": "This one-year study is designed to investigate the safety and efficacy of TPX-100, a\n      23-amino acid chondrogenic peptide, delivered by intra-articular injection, in regeneration\n      of knee cartilage in subjects with bilateral osteoarthritis of the knee."
        }, 
        "brief_title": "A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 25 and \u2264 75\n\n          2. Patello-femoral osteoarthritis of both knees of mild to moderate severity with intact\n             meniscus and ligamentous stability (cruciate and collateral ligaments)\n\n               -  Clinically, as determined by screening questionnaire and  judgment of the\n                  Principal Investigator (may be supported by imaging studies of knees); confirmed\n                  by centrally read screening MRI of both knees indicating ICRS Grade 1-3, or ICRS\n                  Grade 4 with only focal defects, no greater than 1 cm.\n\n               -  Meniscus intact (MRI degenerative signal up to and including grade II\n                  acceptable)\n\n               -  Cruciate and collateral ligament stability as defined by clinical examination\n\n          3. Able to read, understand, sign and date the subject informed consent\n\n          4. Willingness to use only acetaminophen as the primary analgesic (pain-relieving) study\n             medication. The maximum dose of acetaminophen must not exceed 4 grams/day (4000 mg\n             per day).\n\n          5. Willingness to use only hydrocodone/acetaminophen for breakthrough pain during the\n             injection period (through study day 30).\n\n          6. Willingness not to use non-steroidal anti-inflammatory drugs (NSAIDS) such as\n             aspirin, ibuprofen, naproxen for the first 30 days of the study.\n\n          7. Female subjects of child bearing potential who are sexually active (non-abstinent)\n             must agree to and comply with using 2 highly effective methods of birth control (oral\n             contraceptive, implant, injectable or indwelling intrauterine device, condom with\n             spermicide, or sexual abstinence) while participating in the study.\n\n        Exclusion Criteria:\n\n          1. Contraindication to MRI, including: metallic fragments, clips or devices in the\n             brain, eye, or spinal canal; implanted devices that are magnetically programmed;\n             weight > 300 lbs.; moderate or severe claustrophobia; previous intolerance of MRI\n             procedure\n\n          2. ICRS grade greater than Grade 3,  or Grade 4 focal defects greater than 1 cm, as\n             confirmed by centrally-read screening MRI\n\n          3. MRI evidence of inflammatory or hypertrophic synovitis\n\n          4. Prior surgery in the knees, excluding procedures for debridement only (no\n             microfracture)\n\n          5. Joint replacement or any other knee surgery planned in the next 12 months\n\n          6. History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or\n             infectious cause for arthritis\n\n          7. Knee effusion >2+ on the following clinical scale:\n\n               -  Zero = No wave produced on downstroke\n\n               -  Trace = Small wave on medial side with downstroke\n\n               -  1+ = Larger bulge on medial side with downstroke\n\n               -  2+ = Effusion spontaneously returns to medial side after upstroke (no downstroke\n                  necessary)\n\n               -  3+ = So much fluid that it is not possible to move the effusion out of the\n                  medial aspect of the knee\n\n          8. Last viscosupplementation (e.g. Synvisc\u00ae or similar hyaluronic acid product) injected\n             into either  knee < 3 months before screening\n\n          9. Last intra-articular knee injection of corticosteroids < 2 months before screening\n\n         10. Use of any steroids (except inhaled corticosteroids for respiratory problems) during\n             the previous month before screening\n\n         11. Known hypersensitivity to TPX-100\n\n         12. Known hypersensitivity to acetaminophen or hydrocodone\n\n         13. History of arthroscopy in either knee in the last 3 months before screening\n\n         14. History of septic arthritis, gout or pseudo-gout, of either knee in previous year\n             before screening\n\n         15. Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms\n             consistent with meniscal tear)\n\n         16. Patellar chondrocalcinosis on X-Ray\n\n         17. Skin problem, rash or hypersensitivity, affecting either knee at the injection site\n\n         18. Bleeding problem, platelet or coagulation deficiency contraindicating, in the\n             doctor's opinion, any intra-articular injection\n\n         19. Active systemic infection\n\n         20. Current treatment or treatment within the previous 2 years prior to the Screening\n             Visit for any malignancy except basal cell or squamous cell carcinoma of the skin,\n             unless with specific written permission is provided by the Sponsor's medical monitor\n\n         21. Women of childbearing potential who are pregnant, nursing, or planning to become\n             pregnant, and those who do not agree to remain on an acceptable method of birth\n             control throughout the entire study period\n\n         22. Participation in other clinical osteoarthritis drug studies  within one year prior to\n             screening\n\n         23. Currently taking Paclitaxel (mitotic inhibitor), and or Natalizumab (anti-integrin\n             monoclonal antibody).\n\n         24. History of significant liver disease or consumption of more than 3 alcoholic drinks a\n             day. (Definition of one alcoholic drink: 12-ounces of beer, 8-ounces of malt liquor,\n             5-ounces of wine, 1.5-ounces or a \"shot\" of 80-proof distilled spirits or liquor such\n             as gin, rum, vodka, or whiskey)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925261", 
            "org_study_id": "TPX-100"
        }, 
        "intervention": [
            {
                "arm_group_label": "TPX-100 Cohort 2", 
                "intervention_name": "TPX-100 50mg", 
                "intervention_type": "Drug", 
                "other_name": "50mg of TPX-100"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 3", 
                "intervention_name": "TPX-100 100mg", 
                "intervention_type": "Drug", 
                "other_name": "100mg of TPX-100"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 4", 
                "intervention_name": "TPX-100 200mg", 
                "intervention_type": "Drug", 
                "other_name": "200mg of TPX-100"
            }, 
            {
                "arm_group_label": "TPX-100 Cohort 1", 
                "intervention_name": "TPX-100 20mg", 
                "intervention_type": "Drug", 
                "other_name": "20mg of TPX-100"
            }, 
            {
                "arm_group_label": [
                    "TPX-100 Cohort 1", 
                    "TPX-100 Cohort 2", 
                    "TPX-100 Cohort 3", 
                    "TPX-100 Cohort 4"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "knee osteoarthritis", 
            "bilateral", 
            "osteoarthritis"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Renee@medvinresearch.com", 
                    "last_name": "Renne Garcia"
                }, 
                "contact_backup": {
                    "email": "vipul@medvinresearch.com", 
                    "last_name": "Vipul Vineet"
                }, 
                "facility": {
                    "address": {
                        "city": "Covina", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91723"
                    }, 
                    "name": "Medvin Research"
                }, 
                "investigator": {
                    "last_name": "Samy Metyas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lynnsartore@gmail.com", 
                    "last_name": "Lynn Sartore", 
                    "phone": "858-673-4589"
                }, 
                "facility": {
                    "address": {
                        "city": "Poway", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92064"
                    }, 
                    "name": "Arthritis Care and Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "denise.macias@ucdmc.ucdavis.edu", 
                    "last_name": "Denise Macias", 
                    "phone": "916-734-8538"
                }, 
                "contact_backup": {
                    "email": "andrea.nunez@ucdmc.ucdavis.edu", 
                    "last_name": "Andrea Nunez", 
                    "phone": "9167344536"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95827"
                    }, 
                    "name": "UC Davis Center for Musculoskeletal Health"
                }, 
                "investigator": {
                    "last_name": "Nancy Lane, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "splunkett@sbcr.net", 
                    "last_name": "Sharyn Plunkett"
                }, 
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93108"
                    }, 
                    "name": "Dr. Hans Richard Barthel"
                }, 
                "investigator": {
                    "last_name": "Hans R Barthel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees", 
        "overall_contact": {
            "email": "Rcarozza@c3-research.com", 
            "last_name": "Ron Carozza, Pharm D", 
            "phone": "(206) 686-4644"
        }, 
        "overall_contact_backup": {
            "email": "meghan.miller@orthotrophix.com", 
            "last_name": "Meghan Miller, MS", 
            "phone": "510-488-3827"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in cartilage thickness in the patello-femoral compartment from baseline to 12 months", 
            "measure": "Change in cartilage thickness in the patello-femoral compartment as measured on standardized MRI from baseline to 12 months", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "OrthoTrophix, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OrthoTrophix, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}